» Articles » PMID: 21607101

Microenvironment at Tissue Injury, a Key Focus for Efficient Stem Cell Therapy: A Discussion of Mesenchymal Stem Cells

Overview
Date 2011 May 25
PMID 21607101
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Stem cell therapy is not a new field, as indicated by the success of hematopoietic stem cell reconstitution for various hematological malignancies and immune-mediated disorders. In the case of tissue repair, the major issue is whether stem cells should be implanted, regardless of the type and degree of injury. Mesenchymal stem cells have thus far shown evidence of safety, based on numerous clinical trials, particularly for immune-mediated disorders. The premise behind these trials is to regulate the stimulatory immune responses negatively. To apply stem cells for other disorders, such as acute injuries caused by insults from surgical trauma and myocardial infarction, would require other scientific considerations. This does not imply that such injuries are not accompanied by immune responses. Indeed, acute injuries could accompany infiltration of immune cells to the sites of injuries. The implantation of stem cells within a milieu of inflammation will establish an immediate crosstalk among the stem cells, microenvironmental molecules, and resident and infiltrating immune cells. The responses at the microenvironment of tissue injury could affect distant and nearby organs. This editorial argues that the microenvironment of any tissue injury is a key consideration for effective stem cell therapy.

Citing Articles

Exosomes derived from liver failure patients' plasma stimulated mesenchymal stem cells alleviate acute liver failure.

Wang Z, Ling J, You S, Zhu B Stem Cell Res Ther. 2025; 16(1):48.

PMID: 39920768 PMC: 11806533. DOI: 10.1186/s13287-025-04163-2.


In Vitro Cellular and Molecular Interplay between Human Foreskin-Derived Mesenchymal Stromal/Stem Cells and the Th17 Cell Pathway.

Najar M, Merimi M, Faour W, Lombard C, Moussa Agha D, Ouhaddi Y Pharmaceutics. 2021; 13(10).

PMID: 34684029 PMC: 8537928. DOI: 10.3390/pharmaceutics13101736.


Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?.

da Silva K, Gobatto A, Costa-Ferro Z, Cavalcante B, Caria A, de Aragao Franca L Stem Cell Res Ther. 2021; 12(1):425.

PMID: 34315546 PMC: 8314259. DOI: 10.1186/s13287-021-02502-7.


Ultrastructure Morphological Characterization of Different Passages of Rat Dental Follicle Stem Cells at Culture.

Al-Bagdadi F, Barona H, Martinez-Ceballos E, Yao S J Microsc Ultrastruct. 2019; 7(2):57-64.

PMID: 31293886 PMC: 6585478. DOI: 10.4103/JMAU.JMAU_44_18.


Post implantation fate of adipogenic induced mesenchymal stem cells on Type I collagen scaffold in a rat model.

Venugopal B, Fernandez F, Harikrishnan V, John A J Mater Sci Mater Med. 2017; 28(2):28.

PMID: 28108956 DOI: 10.1007/s10856-016-5838-7.


References
1.
Javazon E, Beggs K, Flake A . Mesenchymal stem cells: paradoxes of passaging. Exp Hematol. 2004; 32(5):414-25. DOI: 10.1016/j.exphem.2004.02.004. View

2.
Chow D, Wenning L, Miller W, Papoutsakis E . Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J. 2001; 81(2):675-84. PMC: 1301544. DOI: 10.1016/S0006-3495(01)75732-3. View

3.
Chan J, Tang K, Patel A, Bonilla L, Pierobon N, Ponzio N . Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006; 107(12):4817-24. PMC: 1895812. DOI: 10.1182/blood-2006-01-0057. View

4.
Livingston D, Anjaria D, Wu J, Hauser C, Chang V, Deitch E . Bone marrow failure following severe injury in humans. Ann Surg. 2003; 238(5):748-53. PMC: 1356155. DOI: 10.1097/01.sla.0000094441.38807.09. View

5.
Deans R, Moseley A . Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000; 28(8):875-84. DOI: 10.1016/s0301-472x(00)00482-3. View